30 unchanged sentences
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2021, and the related notes and our report dated February 18, 2022 expressed an unqualified opinion thereon.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 16, 2023 expressed an unqualified opinion thereon.
Basis for Opinion
18 unchanged sentences
Other Information.
−Removed: On February 17, 2022, Brad Crutchfield and 10x Genomics, Inc.
−Removed: (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Mr.
−Removed: Crutchfield will depart the Company after a transition period.
−Removed: Crutchfield has agreed to continue to serve as the Company’s Chief Commercial Officer until a replacement is appointed, after which Mr.
−Removed: Crutchfield will continue to provide transition services to the Company through December 31, 2022 unless Mr.
−Removed: Crutchfield’s employment is terminated prior to such time.
−Removed: Crutchfield’s departure is not due to any disagreement with the Company’s management team, operations, financial statements, policies or procedures.
−Removed: Pursuant to the Agreement, while he is employed by the Company Mr.
−Removed: Crutchfield is entitled to payment of his current base salary and to continue to participate in the employee benefit plans generally available to the Company’s employees and Mr.
−Removed: Crutchfield’s outstanding equity awards will continue to vest.
−Removed: Crutchfield shall also be entitled to a bonus amount equal to twenty eight percent of his current base salary in lieu of an annual performance bonus for the full year 2022 contingent on the Company’s achievement of 2022 revenue goals and Mr.
−Removed: Crutchfield’s satisfactorily completion of transition services under the Agreement (the “Bonus”).
−Removed: If the Company terminates Mr.
−Removed: Crutchfield’s employment without cause prior to December 31, 2022, the Company shall continue to pay Mr.
−Removed: Crutchfield’s current base salary through December 31, 2022, the vesting of Mr.
−Removed: Crutchfield’s equity awards shall accelerate as if Mr.
−Removed: Crutchfield were employed through December 31, 2022, Mr.
−Removed: Crutchfield shall be eligible to earn the Bonus and the Company shall directly pay or reimburse Mr.
−Removed: Crutchfield for COBRA health insurance premiums up to December 31, 2022.
−Removed: Such payments and benefits are conditioned upon Mr.
−Removed: Crutchfield continuing to comply with certain obligations applicable to him and, upon execution and termination, delivery and non-revocation of a general release of claims.
−Removed: The above description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement, which is attached hereto as Exhibit 10.29 and is incorporated herein by reference.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
22 unchanged sentences
Number Exhibit Title Form File No.
−Removed: Exhibit Filing Date
+Added: Exhibit Filing Date Filed Herewith
3.1 Amended and Restated Certificate of Incorporation of the Registrant.
5 unchanged sentences
4.2 Description of the Registrant’s Securities.
+Added: 10-K 001-39035 4.2 2/18/2022
10.1 Agreement for Purchase and Sale, dated August 10, 2020, between the Registrant and Equity One (West Coast Portfolio) LLC.
8 unchanged sentences
S-1/A 333-233361 10.11 9/3/2019
+Added: 10.5.1+ Form of 2019 Omnibus Incentive Plan Stock Option Award Notice and Agreement.
+Added: 10-Q 001-39035 10.1 11/3/2022
+Added: 10.5.2+ Form of 2 019 Omnibus Incentive Plan Restricted Stock Unit Award Notice and Agreement.
+Added: 10-Q 001-39035 10.2 11/3/2022
10.6+ 2019 Employee Stock Purchase Plan and forms of agreements.
10-Q 001-39035 10.4 11/12/2019
+Added: 10.6.1+ Form of 2019 Employee Stock Purchase Plan Subscription Agreement.
+Added: 10.6.2+ Form of 2019 Employee Stock Purchase Plan Notice of Contribution Percentage Change or Withdrawal.
10.7+ Amended and Restated Non-Employee Director Compensation Policy.
−Removed: 8-K 001-39035 10.1 6/2/2021
+Added: 10-Q 001-39035 10.2 5/5/2022
+Added: Incorporated by Reference
+Added: Number Exhibit Title Form File No.
+Added: Exhibit Filing Date Filed Herewith
10.8+ Form of At‑Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement.
10 unchanged sentences
S‑l 333‑233361 10.3 8/19/2019
−Removed: Incorporated by Reference
−Removed: Number Exhibit Title Form File No.
−Removed: Exhibit Filing Date
10.14 First Amendment to Lease Agreement, dated May 20, 2019, between the Registrant and 6200 Stoneridge Mall Road Investors LLC.
6 unchanged sentences
10-Q 001-39035 10.4 11/12/2020
−Removed: 10.18+ Form of Restricted Stock Unit Award under the 2019 Omnibus Incentive Plan.
−Removed: 10‑K 333‑39035 10.7 2/26/2021
−Removed: 10.19+ Form of Incentive Stock Option Award (US Participants) under the 2019 Omnibus Incentive Plan.
−Removed: 10‑K 333‑39035 10.8 2/26/2021
−Removed: 10.20+ Form of Nonqualified Stock Option Award (Board of Directors) under the 2019 Omnibus Incentive Plan.
−Removed: 10‑K 333‑39035 10.9 2/26/2021
−Removed: 10.21+ Form of Nonqualified Stock Option Award (US Participants) under the 2019 Omnibus Incentive Plan.
−Removed: 10‑K 333‑39035 10.10 2/26/2021
−Removed: 10.22+ Form of Nonqualified Stock Option Award (Non‑US Participants) under the 2019 Omnibus Incentive Plan.
−Removed: 10‑K 333‑39035 10.11 2/26/2021
10.18# License Agreement, dated September 26, 2013, between the Registrant and the President and Fellows of Harvard College.
13 unchanged sentences
8-K 001-39035 10.1 7/27/2021
+Added: Incorporated by Reference
+Added: Number Exhibit Title Form File No.
+Added: Exhibit Filing Date Filed Herewith
10.24+ Transition and Separation Agreement between Bradford J.
1 unchanged sentence
dated February 17, 2022.
+Added: 10-K 001-39035 10.29 2/18/2022
+Added: 10.25+ Employment Offer Letter by and between the Registrant and James Wilbur dated July 12, 2022.
+Added: 10-Q 001-39035 10.1 8/9/2022
23.1 Consent of Independent Registered Public Accounting Firm .
3 unchanged sentences
32.1* Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
−Removed: Incorporated by Reference
−Removed: Number Exhibit Title Form File No.
−Removed: Exhibit Filing Date
32.2* Certification of Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
38 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.